Verona Pharma is at an exciting stage of its development with a new proprietary suspension formulation of its first-in-class RPL554. The proposed £44.7m equity capital raise announced Friday, supported by group of US and EU healthcare focused funds, enables the group to progress its development of RPL554 through to a Phase III ready stage. If development goes according to plan, RPL554 could be in a position to commence Phase III trials by the end of 2018. We remain upbeat on Verona and look forw ....
20 Jun 2016
N+1 Singer - Verona Pharma - Funded to Phase III, commitment to NASDAQ listing
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Verona Pharma - Funded to Phase III, commitment to NASDAQ listing
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
20 Jun 2016 -
Author:
Sheena Berry -
Pages:
6
Verona Pharma is at an exciting stage of its development with a new proprietary suspension formulation of its first-in-class RPL554. The proposed £44.7m equity capital raise announced Friday, supported by group of US and EU healthcare focused funds, enables the group to progress its development of RPL554 through to a Phase III ready stage. If development goes according to plan, RPL554 could be in a position to commence Phase III trials by the end of 2018. We remain upbeat on Verona and look forw ....